The expression of MUC5AC in patients with rhinosinusitis: A systematic review and meta-analysis

IF 4.6 2区医学 Q2 ALLERGY Clinical and Translational Allergy Pub Date : 2024-10-31 DOI:10.1002/clt2.70003

Yitao Li

{"title":"The expression of MUC5AC in patients with rhinosinusitis: A systematic review and meta-analysis","authors":"Yitao Li","doi":"10.1002/clt2.70003","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>To understand the connection between Muc5AC expression and the likelihood of rhinosinusitis, with the goal of providing insights into its prospective use as a biomarker.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases for studies up to November 2023 to conduct a literature review. After screening and quality assessment, eligible studies meeting the criteria were included. Muc5AC expression and rhinosinusitis association was analyzed by STATA 14.0.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Including weighted mean difference and 95% confidence interval, were reported. The meta-analysis included 16 studies with 1448 rhinosinusitis patients. MUC5AC expression was significantly up-regulated in both chronic rhinosinusitis with nasal polyps (CRSwNP; WMD: 0.52; 95% CI: 0.41–0.63) and chronic rhinosinusitis without nasal polyps (CRSsNP; WMD: 0.42; 95% CI: 0.28–0.56) patients compared to controls. IHC positive area analysis corroborated these findings, with elevated MUC5AC levels in CRSwNP (WMD: 25.61; 95% CI: 22.41–28.81) and CRSsNP (WMD: 39.74; 95% CI: 25.6–53.88) patients. Subgroup analysis based on tissue type (nasal tissue fluid and sinus mucosa) consistently supported the overall results.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our meta-analysis robustly demonstrates a significant association between elevated MUC5AC expression and rhinosinusitis risk. This finding underscores the potential of MUC5AC as a molecular marker, providing valuable insights for future research and potential therapeutic interventions in rhinosinusitis management.</p>\n </section>\n \n <section>\n \n <h3> Systematic review registration</h3>\n \n <p>CRD42024518932.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"14 11","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

To understand the connection between Muc5AC expression and the likelihood of rhinosinusitis, with the goal of providing insights into its prospective use as a biomarker.

Methods

We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases for studies up to November 2023 to conduct a literature review. After screening and quality assessment, eligible studies meeting the criteria were included. Muc5AC expression and rhinosinusitis association was analyzed by STATA 14.0.

Results

Including weighted mean difference and 95% confidence interval, were reported. The meta-analysis included 16 studies with 1448 rhinosinusitis patients. MUC5AC expression was significantly up-regulated in both chronic rhinosinusitis with nasal polyps (CRSwNP; WMD: 0.52; 95% CI: 0.41–0.63) and chronic rhinosinusitis without nasal polyps (CRSsNP; WMD: 0.42; 95% CI: 0.28–0.56) patients compared to controls. IHC positive area analysis corroborated these findings, with elevated MUC5AC levels in CRSwNP (WMD: 25.61; 95% CI: 22.41–28.81) and CRSsNP (WMD: 39.74; 95% CI: 25.6–53.88) patients. Subgroup analysis based on tissue type (nasal tissue fluid and sinus mucosa) consistently supported the overall results.

Conclusion

Our meta-analysis robustly demonstrates a significant association between elevated MUC5AC expression and rhinosinusitis risk. This finding underscores the potential of MUC5AC as a molecular marker, providing valuable insights for future research and potential therapeutic interventions in rhinosinusitis management.

Systematic review registration

CRD42024518932.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

鼻炎患者体内 MUC5AC 的表达：系统回顾与荟萃分析。

背景：了解Muc5AC的表达与鼻炎可能性之间的联系，目的是为将其用作生物标记物提供见解：了解Muc5AC的表达与鼻炎发病可能性之间的联系，旨在为其作为生物标记物的前瞻性应用提供见解：我们检索了PubMed、Embase、Cochrane图书馆、中国国家知识基础设施和万方数据库中截至2023年11月的研究，并进行了文献综述。经过筛选和质量评估，符合标准的研究被纳入其中。用 STATA 14.0 分析 Muc5AC 表达与鼻炎的关系：包括加权平均差和 95% 置信区间。荟萃分析纳入了 16 项研究，共 1448 例鼻炎患者。与对照组相比，有鼻息肉的慢性鼻炎（CRSwNP；WMD：0.52；95% CI：0.41-0.63）和无鼻息肉的慢性鼻炎（CRSsNP；WMD：0.42；95% CI：0.28-0.56）患者的 MUC5AC 表达均显著上调。IHC 阳性区域分析证实了这些发现，CRSwNP（WMD：25.61；95% CI：22.41-28.81）和 CRSsNP（WMD：39.74；95% CI：25.6-53.88）患者的 MUC5AC 水平升高。基于组织类型（鼻腔组织液和鼻窦粘膜）的亚组分析一致支持总体结果：我们的荟萃分析有力地证明了 MUC5AC 表达升高与鼻炎风险之间存在显著关联。这一发现强调了 MUC5AC 作为分子标记物的潜力，为未来的研究和潜在的鼻炎治疗干预提供了有价值的见解：CRD42024518932。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.